Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration

Retina

Volumn 25, Issue 3, 2005, Pages 296-303

  Loewenstein, Anat ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Drusen

Indexed keywords

ADULT; AGED; AMSLER GRID EXAMINATION; ARTICLE; ATROPHY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; EYE PHOTOGRAPHY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIMETER; PERIMETRY; PREFERENTIAL HYPERACUITY PERIMETER; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PERIMETRY; PHOTOGRAPHY; PREDICTIVE VALUE OF TESTS; REFRACTION, OCULAR; SENSITIVITY AND SPECIFICITY; VISUAL ACUITY;

EID: 17144424207     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200504000-00008     Document Type: Article

References (28)

1. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-943.
2. Pizzarello LD. The dimensions of the problem of eye disease among the elderly. Ophthalmology 1987;94:1191-1195.
3. Bressler NM, Bressler SB. Preventive ophthalmology. Age-related macular degeneration. Ophthalmology 1995;102:1206-1211.
4. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS report no. 8. Arch Ophthalmol 2001;119:1417-1436.
5. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642.
6. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol 1991;109: 1109-1114.
7. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five-year results from randomized clinical trials. Arch Ophthalmol 1994;112:500-509.
8. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 1999;117:1329-1345.
9. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207.
10. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001;131:541-60.
11. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003;136:407-418.
12. Sharma S, Brown GC, Brown NM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108:2051-2059.
13. Fine SL. Early detection of extrafoveal neovascular membranes by daily central field evaluation. Ophthalmology 1985;92:603-616.
14. Fine AM, Elman MJ, Ebert JE, et al. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol 1986;104:513-514.
15. Achard OA, Safran AB, Duret FC, Ragama E. Role of the completion phenomenon in the evaluation of Amsler grid results. Am J Ophthalmol 1995;120:322-329.
16. Wall M, Sadun AA. Threshold Amsler grid testing. Cross-polarizing lenses enhance yield. Arch Ophthalmol 1986;104: 520-523.
17. Roy MS. Vision loss without Amsler grid abnormalities in macular subretinal neovascularization. Ophthalmologica 1985;191:215-217.
18. Schuchard RA. Validity and interpretation of Amsler grid report. Arch Ophthalmol 1993;111:776-780.
19. Gilbert CD, Wiesel TN. Receptive field dynamics in adult primary visual cortex. Nature 1992;356:150-152.
20. Parkes L, Lund J, Angelucci A, et al. Compulsory averaging of crowded orientation signals in human vision. Nat Neurosci 2001:4:739-744.
21. Kaas JH, Krubitzer LA, Chino YM, et al. Reorganization of retinotopic cortical maps in adult mammals after lesions of the retina. Science 1990;248:229-231.
22. Westheimer G. The spatial sense of the eye. Invest Ophthalmol Vis Sci 1979;18:893-912.
23. Enoch JM, Williams RA, Essock EA, Barricks M. Hyperacuity perimetry: assessment of macular function through ocular opacities. Arch Ophthalmol 1984;102:1164-1168.
24. Baraldi P, Enoch JM, Raphael S. Vision through nuclear and posterior subcapsular cataract. Int Ophthalmol 1986;9:173-178.
25. Lakshminarayanan V, Aziz S, Enoch JM. Variation of the hyperacuity gap function with age. Optom Vis Sci 1992;6: 423-426.
26. Bressler SB, Silva JC, Bressler NM, et al. Clinicopathologic correlation of occult choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 1992;110: 827-832.
27. Loewenstein A, Malach M, Goldstein M, et al. Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology 2003;110: 966-970.
28. Altman DG. McNemar's test. In: Practical Statistics for Medical Research. London: Chapman & Hall; 1991:229-272.